Showing 1 - 8 results of 8 for search 'Niklas Schmedt', query time: 0.04s Refine Results
  1. 1
    Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer

    Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer by Niklas Schmedt, Olivia Denise Heuer, Dennis Häckl, Reiko Sato, Christian Theilacker

    Published 2019-01-01
    Get full text
    Article
  2. 2
    Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.

    Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. by Liping Huang, Olivia Denise Heuer, Sabrina Janßen, Dennis Häckl, Niklas Schmedt

    Published 2020-01-01
    Get full text
    Article
  3. 3
    Antidepressants and the risk of death in older patients with depression: A population-based cohort study.

    Antidepressants and the risk of death in older patients with depression: A population-based cohort study. by Bianca Kollhorst, Kathrin Jobski, Jutta Krappweis, Tania Schink, Edeltraut Garbe, Niklas Schmedt

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Pneumococcal vaccination rates in immunocompromised patients-A cohort study based on claims data from more than 200,000 patients in Germany.

    Pneumococcal vaccination rates in immunocompromised patients-A cohort study based on claims data from more than 200,000 patients in Germany. by Niklas Schmedt, Julia Schiffner-Rohe, Ralf Sprenger, Jochen Walker, Christof von Eiff, Dennis Häckl

    Published 2019-01-01
    Get full text
    Article
  5. 5
    Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink

    Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink by Jennifer K Quint, Laurie A Tomlinson, Sarah Cook, Philip A Kalra, Niklas Schmedt, Julie Broughton

    Published 2023-03-01
    Get full text
    Article
  6. 6
    Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

    Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study by Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

    Published 2024-03-01
    Get full text
    Article
  7. 7
    Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

    Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study by Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno

    Published 2024-02-01
    Get full text
    Article
  8. 8
    Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?

    Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? by Sebastian Heinzel, Daniela Berg, Daniela Berg, Sebastian Binder, Georg Ebersbach, Lennart Hickstein, Lennart Hickstein, Heinz Herbst, Michael Lorrain, Ingmar Wellach, Walter Maetzler, Walter Maetzler, Gudula Petersen, Niklas Schmedt, Jens Volkmann, Dirk Woitalla, Volker Amelung

    Published 2018-06-01
    Get full text
    Article

Search Tools: